Ocrelizumab use in the real-world experience: data from a hot spot area for Multiple Sclerosis

被引：0
|
作者：
Mellino, P. [1 ]
Lorefice, L. [1 ]
Pilotto, S. [1 ]
Frau, J. [1 ]
Pintus, M. [1 ]
Barca, S. [1 ]
Coghe, G. [1 ]
Barracciu, M. [2 ]
Cocco, E. [1 ]
机构：
[1] Univ Cagliari, Multiple Sclerosis Ctr, Dept Med Sci & Publ Hlth, ASL Cagliari,Binaghi Hosp, Cagliari, Italy
[2] ASL Cagliari, Binaghi Hosp, Radiol Unit, Cagliari, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-497
引用
收藏
页码：634 / 635
页数：2
相关论文
共 50 条
  • [41] Real world experience with ocrelizumab in patiens with relapsing-remitting multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 301
  • [42] Ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis: a single-center real-world experience
    Lapucci, C.
    Boffa, G.
    Cellerino, M.
    Novi, G.
    Sbragia, E.
    Bruschi, N.
    Mancuso, E.
    Tazza, F.
    Laroni, A.
    Capello, E.
    Uccelli, A.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 177 - 178
  • [43] A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab
    Dillon, P.
    Waqar, A.
    Roumpanis, S.
    Martinec, M.
    Muros-Le Rouzic, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 103 - 104
  • [44] Real-world experience with ocrelizumab in the german neurotransdata registry
    Braune, S.
    Heer, Y.
    Tozzi, V.
    Van Hoevell, P.
    Muros-Le Rouzic, E.
    Dirks, P.
    Bergmann, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 69 - 70
  • [45] Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
    Nasello, Martina
    Zancan, Valeria
    Rinaldi, Virginia
    Marrone, Antonio
    Renie, Roberta
    Diamant, Selene
    Marconi, Martina
    Le Mura, Lorenzo
    Salvetti, Marco
    Buscarinu, Maria Chiara
    Bellucci, Gianmarco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [46] Ocrelizumab extended interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience
    Guerrieri, S.
    Nozzolillo, A.
    Zanetta, C.
    Genchi, A.
    Azzimonti, M.
    Gattuso, I.
    Filippi, M.
    Moiola, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 846 - 847
  • [47] Real-world safety data from up to 4.5 years of ocrelizumab in relapsing and primary progressive multiple sclerosis - a CONFIDENCE interim analysis
    Weber, Martin
    Buttmann, Mathias
    Meuth, Sven
    Bluemich, Sandra
    Dirks, Petra
    Eggebrecht, Julius
    Hieke-Schulz, Stefanie
    Leemhuis, Jost
    Ziemssen, Tjalf
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 373 - 374
  • [48] Real-world experience of ofatumumab in Chinese multiple sclerosis patients
    Tan, Hongmei
    ZhangBao, Jingzi
    Zhou, Lei
    Zhao, Chongbo
    Quan, Chao
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1112 - 1113
  • [49] Ocrelizumab two-year real-world safety and effectiveness over in the treatment of multiple sclerosis
    Vollmer, Brandi
    Ijadi, Nassim
    Declusin, Anthony
    Nair, Kavita
    Sillau, Stefan
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2021, 96 (15)
  • [50] Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
    Monschein, Tobias
    Dekany, Sarinah
    Zrzavy, Tobias
    Ponleitner, Markus
    Altmann, Patrick
    Bsteh, Gabriel
    Kornek, Barbara
    Rommer, Paulus
    Enzinger, Christian
    Di Pauli, Franziska
    Kraus, Jorg
    Berger, Thomas
    Leutmezer, Fritz
    Guger, Michael
    JOURNAL OF NEUROLOGY, 2023, 270 (08) : 3779 - 3786
12345